ERG, an ETS family transcription factor, is known to be expressed in endothelial cells, and oncogenic ERG gene fusions occur in subsets of prostatic carcinoma, acute myeloid leukemia, and Ewing sarcoma. In this study, we immunohistochemically investigated nuclear ERG expression using a new monoclonal antibody, CPDR ERG-MAb, that is highly specific for detecting ERG protein and ERG-expressing prostate carcinomas. A broad range of vascular endothelial (n=250), other mesenchymal (n=973), and epithelial tumors (n=657) was examined to determine the use of ERG immunohistochemistry in surgical pathology. Only immunostains with ERG-positive normal endothelia (internal control) were considered valid, and only nuclear staining was considered to be positive. In adult tissues, ERG was restricted to endothelial cells and to a subset of bone marrow precursors, but early fetal mesenchyme and subpopulations of fetal cartilage were also positive. In vascular tumors, ERG was expressed in endothelia of all hemangiomas and lymphangiomas, and typically extensively expressed in 96 of 100 angiosarcomas, 42 of 43 epithelioid hemangioendotheliomas, and all 26 Kaposi sarcomas. Among nonvascular mesenchymal tumors, only blastic extramedullary myeloid tumors (7 of 10) and rare Ewing sarcomas (2 of 29) were positive. Among epithelial tumors, 30 of 66 prostatic adenocarcinomas showed focal-to-extensive ERG positivity, with no immunoreactivity in the normal prostate. Other carcinomas and epithelial tumors (n=643) were ERG negative, with the exception of 1 of 42 large cell undifferentiated pulmonary carcinomas and 1 of 27 mesotheliomas, each of which showed focal nuclear ERG positivity. On the basis of the above observations, ERG is a highly specific new marker for benign and malignant vascular tumors. Among epithelial tumors, ERG shows a great promise as a marker to identify prostatic carcinoma in both primary and metastatic settings. (Am J Surg Pathol 2011;35:432-441) FIGURE 1. A, Nuclear ERG expression in the primitive subepidermal mesenchyme and vascular endothelial cells in an early first trimester human embryo. B, Developing cartilage, especially peripherally, at the joints and foci of the perichondrial mesenchyme and capillary endothelia showing nuclear ERG positivity in a late first trimester fetus.
S pecific identification of malignant vascular endothelial tumorsFangiosarcoma, Kaposi sarcoma, and epithelioid hemangioendotheliomaFcan be challenging in view of their multiple histologic mimics. Availability of tumortype-specific chemotherapy regimens that include paclitaxel for angiosarcoma has given accurate tumor typing new therapeutic significance. 7 Current markers for angiosarcoma include CD31 (primary marker), 4, 13, 19 CD34, 19, 25, 31, 32 podoplanin (D2-40), 3 and vascular endothelial growth factor receptors 11, 23 as other potential markers. None of these markers have ideal sensitivity and specificity. CD31 is also expressed in some hematopoietic cells, including tissue histiocytes and platelets. 13, 17, 19, 24 CD34 is widely expressed in nonendothelial neoplasms, such as many fibroblastic tumors and gastrointestinal stromal tumors. 32 Vascular endothelial growth factor receptor 3 and podoplanin preferentially identify lymphatic endothelia and some but not all angiosarcomas, and the latter is also expressed in other tumor types, for example, in squamous cell carcinoma and seminoma. 23, 28 Von Willebrand factor (factor VIII-related antigen), being a serum component, is an older marker with a lower detection sensitivity for angiosarcoma and frequent interpretation problems. 19 ETS family transcription factors, including ERG, ETS-1, Freund's leukemia integration site 1 (Fli-1), NERF-2, and TEL, are expressed in vascular endothelial cells and are therefore potential endothelial markers as well. 27 Fli-1, also involved in the most common Ewing sarcoma translocation, is constitutionally expressed in endothelial cells and lymphoid cells. Although 1 immunohistochemical study suggested high specificity and sensitivity of a polyclonal antibody for vascular tumors in addition to Ewing sarcoma, 5 another series also showed common immunoreactivity in synovial sarcoma, melanoma, and pulmonary adenocarcinoma. 26 ERG (avian v-ets erythroblastosis virus E26 oncogene homolog), member of the ETS family transcription factors, is constitutionally expressed in endothelial cells regulating angiogenesis and endothelial apoptosis. 2 ERG has been recently studied immunohistochemically in prostate carcinoma, subsets of which have oncogenic TMPRSS2-ERG gene fusions and express ERG protein, and in human tissues, vascular endothelial cells also consistently express ERG. 6, 21, 30 In this study, we explored ERG as an immunohistochemical marker in the study of vascular tumors, of which no data exist on ERG expression. We also examined a large number of nonepithelial and epithelial neoplasms to explore the specificity of ERG for vascular tumors and also for prostate carcinoma among carcinomas. On the basis of our observations, ERG has a high sensitivity and specificity for endothelial malignancies. The other known entities for ERG gene fusions, acute myeloid leukemia (AML), and Ewing sarcoma, are among rare exceptions on positive nonendothelial neoplasms. In contrast, ERG is highly specific for prostate carcinoma among epithelial tumors, and is expected to be useful in the assessment of prostate carcinoma and metastases of prostatic origin.
MATERIALS AND METHODS
A wide variety of normal (n>100) and neoplastic tissues of different lineages (n=1880) were immunohistochemically examined for ERG expression. For these studies, we mainly used sections generated from multitissue blocks containing 5 to 50 different tissue samples. Additional cases of vascular tumors were examined on slides prepared from conventional tissue blocks. To create an understanding of ERG tissue distribution, adult and fetal human tissues from surgical specimens were also studied.
Monoclonal antibody to ERG (CPDR ERG-MAb) prepared from a synthetic peptide of an N-terminal sequence of ERG protein was used. The final concentration of 3.7 mg/mL (1:1000 dilution of reconstituted purified antibody stock). This antibody was prepared at the Center for Prostate Disease Research of Walter Reed Army Medical Center and Uniformed Services University (Rockville, MD). It has been shown to be specific to ERG by immunoblotting and by the evaluation of ERGnegative and ERG-positive cell lines, with no crossreaction with other ETS family proteins, such as Fli-1. 20 Furthermore, it selectively identifies ERG gene-translocated subset of prostate carcinomas. 6 Immunostaining was performed on the Leica Bond-Max automatic immunostainer (Leica, Bannockburn, IL). Heat-induced epitope retrieval (high pH, ethylenediaminetetraacetic acid-based buffer, pH 9.0, Leica Bond-Max) for 25 minutes, followed by normal goat serum (Vector, Burlingame, CA; dilution 1:10), which was applied for 10 minutes before applying the primary antibody. The primary antibody was incubated for 30 minutes at room temperature. A Leica Bond-Max avidinbiotin-free polymer system was used in the detection according to the company's recommended procedure. Diaminobenzidine was used as the chromogen after blocking of endogenous peroxidase with 3% hydrogen peroxide diluted in phosphate buffer. Finally, a light hematoxylin counterstain was applied.
The portion of positive tumor cell nuclei was semiquantitatively assessed. Only nuclear immunoreactivity was counted as positive, and only cases with positive normal endothelial staining (internal control) were scored. On the basis of this immunoreactivity, approximately 5% of cases were excluded from the study. These cases especially included acid-decalcified tissue, tissues obtained from autopsies, and very old unstained slides. Monoclonal antibody, JC70A, to CD31 (Dako Cytomation, Carpinteria, CA), diluted at 1:100, with similar epitope retrieval as used for ERG, was used in the characterization of vascular tumors. Monoclonal antibody to smooth muscle actin (Clone 1A4; Sigma Chemicals, St Louis, MO), diluted at 1:32000, with no pretreatment, was used in the characterization of pericytic populations in vascular tumors. Von Willebrand factor (factor VIII-related antigen) was not used in this study as a marker because of its known lower sensitivity in the detection of angiosarcomas.
RESULTS

Normal Human Adult and Developing Tissues
In normal adult tissues [the skin, breast, tonsil, spleen, thymus, lung, esophagus, stomach, small intestine, colon, liver, pancreas, kidney, urinary bladder, prostate, seminal vesicle, epididymis, testis, endometrium, myometrium, (postmenopausal) ovary, adrenal gland, thyroid, parathyroid, brain, and mesothelia] ERG expression was restricted to vascular endothelial cells. Vascular pericytes and smooth muscle cells were ERG negative.
In an adult bone marrow, a subpopulation of immature myeloid cells was ERG positive. In these tissues, nuclei of endothelia of blood vessels of various calibers and lymphatics were equally highlighted. Pericytes and vascular smooth muscle were consistently negative. No adult epithelial, other mesenchymal, neuroectodermal, or lymphoid cells were positive.
In an early first trimester human embryo, subepidermal and paraspinal mesenchyme showed nuclear positivity, in addition to endothelial cells (Fig. 1A) . The spinal cord and differentiating epithelial and mesenchymal elements in single profiles of the lung, heart, liver, and gastrointestinal tract were negative. In a late first trimester fetus, nuclear ERG positivity was detected in the periphery of cartilage, especially at the joints, and focally in the perichondrial mesenchyme, but was otherwise restricted to endothelial cells in the small intestine, kidney, liver, and spleen ( Fig. 1B) . In term, first and second trimester placenta, ERG was also restricted to endothelial cells, and yolk sac and placental trophoblast were negative.
Vascular Endothelial Tumors
Nuclear positivity was uniformly detected in hemangiomas of different types and in lymphangiomas and lymphangioendotheliomas ( Fig. 2 ). Pericytic elements, also detected by smooth muscle actin immunostaining and especially prominent in cellular hemangiomas, such as juvenile capillary hemangioma, were negative ( Fig. 2A ). In spindle cell hemangioma, the nuclei of vascular lumen-lining endothelial cells were positive, whereas the interstitial spindle cells were negative ( Table 1 , Fig. 2D ).
In retiform hemangioendothelioma, the neoplastic endothelial cells were uniformly ERG positive (Fig. 3A) . In epithelioid hemangioendothelioma, virtually, all tumor cell nuclei in the infiltrative cords were highlighted as ERG positive, and cytoplasmic staining was also present ( Table 1 , Fig. 3B ). In kaposiform hemangioendothelioma, the endothelial cells were ERG positive, but the abundant pericytic component (also smooth muscle actin-positive) was ERG negative (Fig. 3C ). A similar situation was observed in a Dabska-type papillary intravascular lymphangioendothelioma.
All but 4 of 100 angiosarcomas (96%) of different types, clinicopathologic subgroups, and different sites, confirmed as CD31 positive in this study, showed nuclear ERG immunoreactivity (Table 1 ). This varied from 5% to 100% (median, 100%). In addition to the 4 negative cases, only 4 cases showed ERG immunoreactivity in <30% of the tumor cells, and only 8 cases in 30% to 49% of tumor cells. Nuclear ERG staining was equally seen in differentiated, vasoformative areas and in undifferentiated, solid, and rare pleomorphic areas (Figs. 4A-C). In contrast to hemangioma, a distinct ERG-negative (pericytic) cell population was generally absent. In angiosarcoma, cytoplasmic ERG positivity was variably present, but less prominent than observed in epithelioid hemangioendothelioma. In mitotic cells, nuclear ERG positivity was exceptionally undetectable (Fig. 4C ). In Kaposi sarcoma, both endothelial cells and neoplastic spindle cells showed nuclear ERG positivity.
All vascular-related, nonendothelial tumors, such as hemangiopericytoma (both peripheral and central nervous system meningeal examples), cerebellar hemangioblastoma, and glomus tumor cells were negative, with endothelial cells only being ERG positive. Highly vascular or hemorrhagic angiosarcoma or Kaposi sarcoma mimics, such as angiomatoid (n=28) and aneurysmal fibrous histiocytoma (n=3), were also ERG negative.
Other Nonepithelial and Epithelial Tumors
A wide array of mesenchymal, neuroectodermal, and hematopoietic tumors was negative for ERG with no nuclear positivity in the neoplastic elements ( Table 2 ). This included epithelioid hemangioendothelioma mimics with corded patterns and myxohyaline stroma, such as primary and metastatic carcinomas, sclerosing perineurioma, chordoma, and extraskeletal myxoid chondrosarcoma. None of the metastatic melanomas showed nonendothelial ERG immunoreactivity.
The exceptions were blastic extramedullary myeloid tumors (AML tissue infiltrates), of which 7 of 10 were ERG positive, usually with uniform nuclear labeling ( Fig. 5A ). In addition, 2 of 29 Ewing sarcomas showed nuclear ERG immunoreactivity ( Fig 5B) . None of the 25 myxoid liposarcomas were ERG positive in our studies.
Chondrosarcomas of different types were tested in view of primitive mesenchymal and perichondrial ERG positivity in embryonal tissue. However, all conventional, dedifferentiated, and mesenchymal chondrosarcomas were negative.
Epithelial Neoplasms
ERG positivity was present in nearly half of prostate carcinomas: 30 of 66 (45.4%), most of which were old transurethral electroresection specimens (Table 3 ). Positivity was encountered in well differentiated and poorly differentiated high-grade tumors, and in intraepithelial neoplasia components, in some cases only as a focal finding (Fig. 5C ). However, there was some tendency for higher frequency in high-grade tumors. In all these specimens, normal prostatic epithelia were negative. Three of 6 metastatic prostate carcinomas of abdominal and neck lymph nodes were also positive.
Among the exceptional nonprostatic epithelial malignancies showing ERG immunoreactivity, there were 1 pulmonary large cell undifferentiated carcinoma (1 of 42) and 1 pleural epithelial, tubulopapillary mesothelioma (1 of 27), each of which showed nuclear ERG immunoreactivity in sporadic tumor cells ( Fig. 5D ).
Cytoplasmic ERG immunoreactivity without nuclear positivity was also seen in some nonendothelial tumors. This was most commonly observed in gastrointestinal stromal tumors, and occasionally in carcinomas, especially in ductal carcinoma of the breast and thyroid papillary carcinoma with the latter showing membrane staining. ERG expression was absent in the neoplastic cells of hemorrhagic, poorly differentiated, or neuroendocrine carcinomas that histologically sometimes simulate angiosarcoma (Fig. 6 ).
DISCUSSION
In this study, we evaluated a large number of normal tissues and vascular and nonvascular mesenchymal tumors, other nonepithelial tumors, and various carcinomas, to examine the potential of ERG transcription factor as an immunohistochemical marker. This was based on the expression of ERG in endothelial cells, as noted in animal models (sea urchin 1 and mouse 20, 33 ) and in human endothelial cell lines 10 and tissues. 6, 21 We also explored ERG as a tissue-type-specific marker for prostate carcinoma among carcinomas, because nearly 50% of prostate carcinomas are known to harbor TMPRSS2-ERG gene fusion translocations and express ERG. 6, 21 Our findings show ERG as a highly specific vascular endothelial marker in normal adult tissues. However, in adult bone marrow, it is also expressed in some myeloid precursor cells, probably including the marrow stem cells known to express ERG. 15 In addition, in human fetal tissue, ERG is additionally expressed in subsets of primitive mesenchymal cells, subsequently being restricted to the peripheral portions of cartilage and perichondrial mesenchyme in the late first trimester. This seems to mirror ERG distribution observed in mouse embryos by RNA in situ hybridization 33 and immunohistochemical studies. 20 Nevertheless, we were not able to find ERG expression in neoplastic cartilage in conventional, mesenchymal, dedifferentiated, or extraskeletal myxoid chondrosarcomas. On the basis of our observations, ERG immunoreactivity is consistently present in the endothelial components of various hemangiomas. The presence of a dual cell population, ERG-positive endothelial cells, and ERG-negative nonendothelial components (especially, pericytes), could be helpful to support the diagnosis of hemangioma over angiosarcoma in some instances, especially, highly cellular hemangiomas. In contrast, angiosarcoma generally has only ERG-positive endothelial components. This is similar to the application of smooth muscle actin immunohistochemistry to detect complete, pericyte-positive vascular differentiation in hemangioma versus angiosarcoma; the latter does not typically contain a smooth muscle actin-positive pericytic component. 9 ERG is also conserved in malignant vascular endothelial neoplasms (hemangioendotheliomas, angiosarcomas, and Kaposi sarcoma) to be a new promising marker for these tumors. The staining is usually seen in a great majority of tumor cells indicating that the expression of the ERG transcription factor in endothelial cells and angiosarcomas is an all-or-none phenomenon. ERG is also useful in separating angiosarcomas and epithelioid hemangioendotheliomas from their histologic mimics, such as nonendothelial tumors with corded, myxohyaline, and hemorrhagic, highly vascular patterns. In angiosarcomas and related tumors, ERG expression may be a constitutional phenotypic feature unrelated to ERG gene rearrangements, although a possible oncogenic role or ERG in vascular tumors cannot be ruled out. The ubiquitous expression of ERG in endothelial tumors necessitates the use of other markers to differentiate between various tumor types, such as angiosarcoma and Kaposi sarcoma.
ERG compares favorably with presently widely used endothelial markers, including CD31, the current gold standard in the definition of angiosarcoma. On account of its global but highly endothelium-restricted expression, ERG immunoreactivity is straightforward to interpret. In contrast, the interpretation of CD31 can be problematic considering its presence in hematopoieticderived cells, especially tissue histiocytes and plasma cells, which can be a diagnostic pitfall leading to an overdiagnosis of angiosarcoma. 17, 19 In addition, the presence of CD31 in platelets can cause diffuse immunoreactivity in areas of hemorrhage and necrosis, complicating the interpretation of CD31 immunostaining in tumor cells. 24 In view of the immunohistochemical complexity of many angiosarcomas, including common expression of some simple epithelial (low molecular weight) keratins, 18 ERG is helpful in the distinction of hemorrhagic, poorly differentiated, and neuroendocrine carcinomas from angiosarcomas. In our experience, these tumors were occasionally incorrectly diagnosed as angiosarcomas before the use of current immunohistochemical markers. Nonendothelial vascular-related tumors, such as glomus tumor, hemangiopericytoma/solitary fibrous tumor, and cerebellar hemangioblastoma, were uniformly negative for ERG, except for endothelial expression, supporting the nonendothelial phenotype of these tumors. In some cases, highly vascular hemangiopericytomas can resemble angiosarcomas, so that ERG immunohistochemistry can be useful in this distinction.
With a few exceptions, ERG is highly specific for vascular endothelial neoplasms. We tested a wide range of tumors, including entities with known ERG fusion translocations, such as Ewing sarcoma, AML, and myxoid liposarcomas. Blastic extramedullary myeloid tumors (AML infiltrates/tissue relapses) showed a high frequency of immunohistochemical ERG positivity (7 of 10). A subset of AMLs contains ERG-involving gene fusions 12 and express ERG (as measured by messenger RNA content), and these especially include poor prognosis of AMLs. 16 Such aggressive tumors could be overrepresented among the ERG-positive blastic extramedullary myeloid tumors. The high frequency of ERG expression in blastic extramedullary myeloid tumors (AML tissue infiltrates) may alternatively indicate that such expression is not restricted to ERG-involving translocation cases. The expression of ERG in normal hematopoietic stem cells also suggests this possibility. 15 In our study, genetic correlation for blastic extramedullary myeloid tumors was not available.
Among Ewing sarcomas, 2 of 29 cases were positive. This frequency matches with the known approximately 10% frequency of EWSR1-ERG gene fusion in Ewing sarcoma. 8, 14 However, the ERG-fusion status was not known in our cases. ERG-involving gene fusions have also been detected in a rare subset of myxoid liposarcoma. 22 Thus, ERG immunoreactivity would be expected to be detectable in some examples, although it was not found in our relatively limited number of cases studied.
The most notable ERG-expressing nonvascular, nonmesenchymal tumor is prostate carcinoma. In this study, 30 of 66 cases were positive, including regional and distant nodal metastases. This mirrors 2 recent studies, in which nearly 50% of prostate cancers were found to contain ERG immunoreactivity, specifically including prostate carcinomas with TMPRSS2-ERG gene fusions that lead to the overexpression of ERG. 6, 21 On the basis of our observations of ERG immunoreactivity in 2 of 549 (0.4%) nonprostatic epithelial malignancies of different types and sites, ERG expression is highly restricted to prostate carcinoma among epithelial cancers. It is conserved in metastases, as shown earlier in regional lymph nodes, 6 and is sufficiently prevalent (approximately 50%) to serve as a useful immunohistochemical marker to explore the possible prostatic origin of a metastatic carcinoma, in a manner similar to other transcription factors, TTF1 for pulmonary carcinoma and CDX2 in gastrointestinal carcinoma. Our findings also support earlier observations of restriction of ERG immunoreactivity to prostatic carcinoma versus non-neoplastic epithelia, 6 so that ERG could also serve as a "malignancy marker" in prostate biopsies. Additional studies are warranted in this respect.
The very occasional nonprostatic, ERG-positive epithelial malignancies included 1 pulmonary large cell carcinoma and 1 epithelial mesothelioma, each with only focal ERG expression. The significance of these observations remains unclear, but possible mechanisms could include sporadic ERG-involving translocations or other gene rearrangements inducing ERG overexpression in nonprostatic carcinomas. ERG-involving translocations have also been detected in uterine cervical carcinoma lines. 29 However, in this study, we were not able to find ERG immunoreactivity in cervical squamous cell carcinomas, suggesting that ERG expression is not a common finding in these tumors in vivo. In conclusion, the ERG transcription factor shows a conserved expression and narrow tissue distribution in both benign and malignant vascular endothelial cells, and is therefore a promising new marker in the identification of angiosarcoma, Kaposi sarcoma, and hemangioendotheliomas. In contrast, the common presence of ERG in prostatic carcinoma and its extremely rare expression in other epithelial malignancies make it a suitable marker in the search of possible prostatic origin for a metastatic carcinoma. However, the absence of ERG in non-neoplastic prostate tissue indicates the potential for ERG as a marker for prostatic malignancy. ERG expression in other tumors, such as blastic extramedullary myeloid tumor/acute myeloid leukemia, Ewing sarcoma, and occasional carcinomas and mesothelioma, must be recognized and mitigated by the use of appropriate immunohistochemical panels in the differential diagnosis.
